Biogen Q3 Adjusted EPS $4.36 Beats $3.99 Estimate, Sales $2.53B Beat $2.39B Estimate
Portfolio Pulse from Benzinga Newsdesk
Biogen reported Q3 earnings of $4.36 per share, beating the analyst consensus estimate of $3.99 by 9.27%. However, this is an 8.6% decrease from the same period last year. The company also reported quarterly sales of $2.53 billion, beating the estimate of $2.39 billion by 5.86%, marking a 0.86% increase from last year.
November 08, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Biogen's Q3 earnings and sales beat estimates, but earnings are down 8.6% from last year. Sales increased slightly by 0.86% from last year.
While Biogen beat earnings and sales estimates, the decrease in earnings from last year might concern investors. The slight increase in sales might not be enough to offset this concern, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100